Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

Authors:
Sanjeevani Arora Rodion Velichinskii Randy W Lesh Usman Ali Michal Kubiak Pranshu Bansal Hossein Borghaei Martin J Edelman Yanis Boumber

Adv Ther 2019 10 13;36(10):2638-2678. Epub 2019 Aug 13.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

In the last few years, immunotherapy has transformed the way we treat solid tumors, including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable responses and long-term survival benefit has been experienced by many cancer patients, with favorable toxicity profiles of immunotherapeutic agents relative to chemotherapy. Cures have become possible in some patients with metastatic disease. Additional approvals of immunotherapy drugs and in combination with other agents are anticipated in the near future. Multiple additional immunotherapy drugs are in earlier stages of clinical development, and their testing in additional tumor types is under way. Despite considerable early success and relatively fewer side effects, the majority of cancer patients do not respond to checkpoint inhibitors. Additionally, while the drugs are generally well tolerated, there is still the potential for significant, unpredictable and even fatal toxicity with these agents. Improved biomarkers may help to better select patients who are more likely to respond to these drugs. Two key biologically important predictive tissue biomarkers, specifically, PD-L1 and mismatch repair deficiency, have been FDA-approved in conjunction with the checkpoint inhibitor, pembrolizumab. Tumor mutation burden, another promising biomarker, is emerging in several tumor types, and may also soon receive approval. Finally, several other tissue and liquid biomarkers are emerging that could help guide single-agent immunotherapy and in combination with other agents. Of these, one promising investigational biomarker is alteration or deficiency in DNA damage response (DDR) pathways, with altered DDR observed in a broad spectrum of tumors. Here, we provide a critical overview of current, emerging, and investigational biomarkers in the context of response to immunotherapy in solid tumors.

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s12325-019-01051-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778545PMC
October 2019

Publication Analysis

Top Keywords

solid tumors
12
patients respond
8
combination agents
8
immunotherapy drugs
8
cancer patients
8
tumor types
8
immunotherapy solid
8
immunotherapy
6
biomarkers
5
improved biomarkers
4
biomarkers help
4
help better
4
agents improved
4
better select
4
toxicity agents
4
select patients
4
response immunotherapy
4
biologically predictive
4
respond drugs
4
drugs key
4

Keyword Occurance

Similar Publications

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.

Authors:
Daniel V Kalinovsky Alexey V Kibardin Irina V Kholodenko Elena V Svirshchevskaya Igor I Doronin Mariya V Konovalova Maria V Grechikhina Fedor N Rozov Sergey S Larin Sergey M Deyev Roman V Kholodenko

J Immunother Cancer 2022 Jun;10(6)

Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia

Background: Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs against solid tumors. This is the first study to analyze cytotoxic activity of clinically relevant anti-GD2 ADCs in a wide panel of cell lines with varying GD2 expression and their effects in mouse models of GD2-positive solid cancer.

Methods: Anti-GD2 ADCs were generated based on the GD2-specific antibody ch14. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.

Authors:
Christine M Minnar Paul L Chariou Lucas A Horn Kristin C Hicks Claudia Palena Jeffrey Schlom Sofia R Gameiro

J Immunother Cancer 2022 Jun;10(6)

Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

Background: Immune checkpoint blockade (ICB) has achieved unprecedented success in treating multiple cancer types. However, clinical benefit remains modest for most patients with solid malignancies due to primary or acquired resistance. Tumor-intrinsic loss of major histocompatibility complex class I (MHC-I) and aberrations in antigen processing machinery (APM) and interferon gamma (IFN-γ) pathways have been shown to play an important role in ICB resistance. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [Ga]Ga-PSMA-617.

Authors:
Qiaomiao Lu Yu Long Kevin Fan Zhiwen Shen Yongkang Gai Qingyao Liu Dawei Jiang Weibo Cai Chidan Wan Xiaoli Lan

Eur J Nucl Med Mol Imaging 2022 Jun 28. Epub 2022 Jun 28.

Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan, 430022, China.

Objective: Hepatocellular carcinoma (HCC) is a malignant tumor associated with high morbidity and mortality rates. In many non-prostate solid tumors such as HCC, prostate-specific membrane antigens (PSMA) are overexpressed in tumor-associated endothelial cells. Therefore, the aim of this study was to evaluate the performance of [Ga]Ga-PSMA-617 PET imaging on HCC with different animal models, including cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), and to explore its mechanisms of function. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Hypoxia-induced polypoid giant cancer cells in glioma promote the transformation of tumor-associated macrophages to a tumor-supportive phenotype.

Authors:
Yuyang Liu Ying Shi Mengwan Wu Jialin Liu Hong Wu Chuan Xu Ling Chen

CNS Neurosci Ther 2022 Jun 28. Epub 2022 Jun 28.

Department of Neurosurgery, Chinese PLA General Hospital, Beijing, China.

Aims: Polypoid giant cancer cells (PGCCs) represent a unique subgroup of stem-like cells, acting as a critical factor in promoting the recurrence of various solid tumors. The effect of PGCCs on the tumor malignancy of glioma and its immune microenvironment remains unclear.

Methods: Bioinformatic analysis was performed to investigate the relationship between M2 tumor-associated macrophages (TAMs) infiltration and survival of glioblastoma (GBM) patients. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Demographic Profile of Benign and Malignant Oral Tumors in Central India: A Retrospective Comparative Study.

Authors:
Suhani Ghai Yogesh Sharma

Cureus 2022 May 26;14(5):e25345. Epub 2022 May 26.

Oral and Maxillofacial Surgery, Netaji Subhash Chandra Bose (NSCB) Medical College, Jabalpur, IND.

Background:  Oral malignancy is endemic in India due to high addiction to tobacco and betel nuts. In addition, benign oral tumors are also very common in India. Studies comparing the demographic profile of benign and malignant oral tumors are scarce in India. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}